VKTX - Viking Therapeutics, Inc.
32.98
1.470 4.457%
Share volume: 2,947,342
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.26%
PREVIOUS CLOSE
CHG
CHG%
$31.51
1.47
0.05%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 04-25-2024 | 07-24-2024 | 10-23-2024 | 02-26-2025 | 04-24-2025 | 07-23-2025 | 10-22-2025 | 02-11-2026 | |
| Assets | |||||||||
| Total Assets | 967.518 M | 946.839 M | 937.888 M | 908.321 M | 866.993 M | 827.851 M | 739.415 M | 715.729 M | |
| Current Assets | 966.335 M | 945.724 M | 936.649 M | 907.216 M | 866.023 M | 827.017 M | 738.703 M | 715.598 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 767.397 M | 898.348 M | 880.093 M | 875.936 M | 813.918 M | 773.844 M | 614.194 M | 539.929 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 195.579 M | 43.915 M | 50.347 M | 26.676 M | 37.940 M | 33.880 M | 100.376 M | 165.810 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 1.085 M | 1.010 M | 1.159 M | 1.049 M | 938.000 K | 826.000 K | 712.000 K | 131.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 967.518 M | 946.839 M | 937.888 M | 908.321 M | 866.993 M | 827.851 M | 739.415 M | 715.729 M | |
| Total liabilities | 33.626 M | 25.859 M | 26.440 M | 28.043 M | 20.075 M | 32.390 M | 26.385 M | 76.667 M | |
| Total current liabilities | 32.774 M | 25.093 M | 25.685 M | 27.413 M | 19.573 M | 31.980 M | 26.067 M | 76.667 M | |
| Accounts Payable | 5.225 M | 11.090 M | 254.000 K | 9.813 M | 7.702 M | 5.494 M | 4.413 M | 53.251 M | |
| Other liabilities | 852.000 K | 766.000 K | 755.000 K | 630.000 K | 502.000 K | 410.000 K | 318.000 K | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 852.000 K | 766.000 K | 755.000 K | 630.000 K | 502.000 K | 410.000 K | 318.000 K | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 935.491 M | 923.252 M | 909.816 M | 881.066 M | 847.134 M | 795.627 M | 712.656 M | 639.062 M | |
| Common stock | 1.341 B | 1.351 B | 1.362 B | 1.369 B | 1.381 B | 1.395 B | 1.403 B | 1.486 B | |
| Retained earnings | -405.299 M | -427.550 M | -452.490 M | -487.907 M | -533.536 M | -599.097 M | -689.884 M | -847.546 M |